Determining the Prevalence of HIV-Related Neurological Disorders in the Asia Pacific

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2007 by National Institute of Mental Health (NIMH).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
The Alfred
Information provided by:
National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT00168246
First received: September 13, 2005
Last updated: February 26, 2007
Last verified: February 2007

September 13, 2005
February 26, 2007
June 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00168246 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Determining the Prevalence of HIV-Related Neurological Disorders in the Asia Pacific
A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region

This study will determine the prevalence of HIV-related neurological disorders in the countries of the Asia-Pacific Region.

This a cross-sectional study to determine the prevalence of HIV-related Neurological Disorders in the countries of the Asia-Pacific Region. Researchers will visit each country site for a period of 2-3 weeks and work with local investigators. Outpatients will be evaluated once-only for the presence of HIV-related symptomatic peripheral neuropathy and HIV-related Neurocognitive Impairment. Inpatients at the sites will be evaluated once-only for the presence of HIV dementia, cerebral toxoplasmosis, cerebral tuberculosis, cryptococcal meningitis, lymphoma, PML and CMV encephalitis.

The Primary outcomes are:

  1. To determine the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites
  2. To determine the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites
  3. To determine the prevalence of central nervous system opportunistic infections and tumours at the APNAC-10 sites

The secondary outcomes are:

To determine the degree of cognitive impairment in patients presenting with HIV-related cognitive impairment at the APNAC-10 sites

  • To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior AIDS defining illnesses (ADIs) of patients presenting with HIV-related neurocognitive impairment and ADC at the APNAC-10 sites
  • To compare the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
  • To compare the prevalence of HIV-related neurocognitive impairment and ADC between the APNAC-10 sites
  • To describe the severity of symptoms of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites
  • To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior ADIs of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites
  • To determine what proportion of symptomatic peripheral sensory neuropathy may be ascribed to HIV alone, to the use of nucleoside analogues
  • To compare the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
  • To compare the prevalence of symptomatic peripheral sensory neuropathy between the APNAC-10 sites
  • To determine the prevalence of asymptomatic peripheral neuropathy
  • To describe the presenting symptoms and signs of patients presenting with CNS OIs and tumours at the APNAC-10 sites
  • To describe the neuroradiological findings of patients presenting with CNS OIs and tumours at the APNAC-10 sites
  • To determine the serological, culture and other diagnostic test results of patients presenting with CNS OIs and tumours at the APNAC-10 sites
  • To determine the CD4 cell counts, HIV viral loads and prior ADIs of patients presenting with CNS OIs and tumours at the APNAC-10 sites
  • To compare the prevalence of CNS OIs and tumours at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
  • To compare the prevalence of CNS OIs and tumours between the APNAC-10 sites
Observational
Observational Model: Natural History
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Not Provided
Not Provided
  • HIV Infections
  • HIV Related Neurological Diseases
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
600
Not Provided
Not Provided

Inclusion Criteria:

  • Patients are HIV infected
  • Patients are eighteen years or older
Both
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT00168246
77/05
Not Provided
Not Provided
National Institute of Mental Health (NIMH)
  • The Alfred
  • National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Edwina Wright, Dr The Alfred Hospital
National Institute of Mental Health (NIMH)
February 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP